» Articles » PMID: 17245597

The Impact of Different Chelating Leaving Groups on the Substitution Kinetics of Mononuclear Pt(II)(1,2-trans-R,R-diaminocyclohexane)(X-Y) Complexes

Overview
Publisher Springer
Specialty Biochemistry
Date 2007 Jan 25
PMID 17245597
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

A set of three oxaliplatin derivatives containing 1,2-trans-R,R-diaminocyclohexane (dach) as a spectator ligand and different chelating leaving groups X-Y, viz., [Pt(dach)(O,O-cyclobutane-1,1-dicarboxylate)], or Pt(dach)(CBDCA), [Pt(dach)(N,O-glycine)]+, or Pt(dach)(gly), and [Pt(dach)(N,S-methionine)]+, or Pt(dach)(L-Met), where L-Met is L-methionine, were synthesized and the crystal structure of Pt(dach)(gly) was determined by X-ray diffraction. The effect of the leaving group on the reactivity of the resulting Pt(II) complexes was studied for the nucleophiles thiourea, glutathione (GSH) and L-Met under pseudo-first-order conditions as a function of nucleophile concentration and temperature, using UV-vis spectrophotometric techniques. 1H NMR spectroscopy was used to follow the substitution of the leaving group by guanosine 5'-monophosphate (5'-GMP2-) under second-order conditions. The rate constants indicate for all reactions a direct substitution of the X-Y chelate by the selected nucleophiles, thereby showing that the nature of the chelate, viz., O-O (CBDCA2-), N-O (glycine) or S-N (L-Met), respectively, plays an important role in the kinetic and mechanistic behavior of the Pt(II) complex. The k1 values for the reaction with thiourea, L-Met, GSH and 5'-GMP2- were found to be as follows (10(3) k1, 37.5 degrees C, M(-1) s(-1)): Pt(dach)(CBDCA) 61 +/- 2, 21.6 +/- 0.1, 23 +/- 1, 0.352 +/- 0.002; Pt(dach)(gly) 82 +/- 3, 6.2 +/- 0.2, 37 +/- 1, 1.77 +/- 0.01; Pt(dach)(L-Met) (thiourea, GSH) 62 +/- 2, 24 +/- 1. The activation parameters for all reactions studied suggest an associative substitution mechanism.

Citing Articles

Biological Evaluation of Dinuclear Platinum(II) Complexes with Aromatic -Heterocycles as Bridging Ligands.

Lukovic D, Franich A, Zivkovic M, Rajkovic S, Stojanovic B, Gajovic N Int J Mol Sci. 2024; 25(15).

PMID: 39126093 PMC: 11312983. DOI: 10.3390/ijms25158525.


Equilibrium Studies on Pd(II)-Amine Complexes with Bio-Relevant Ligands in Reference to Their Antitumor Activity.

Shoukry M, van Eldik R Int J Mol Sci. 2023; 24(5).

PMID: 36902279 PMC: 10003265. DOI: 10.3390/ijms24054843.


Oxaliplatin reacts with DMSO only in the presence of water.

Varbanov H, Ortiz D, Hofer D, Menin L, Galanski M, Keppler B Dalton Trans. 2017; 46(28):8929-8932.

PMID: 28654098 PMC: 9272996. DOI: 10.1039/c7dt01628j.


A Potent Glucose-Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer Cells.

Patra M, Johnstone T, Suntharalingam K, Lippard S Angew Chem Int Ed Engl. 2016; 55(7):2550-4.

PMID: 26749149 PMC: 4752825. DOI: 10.1002/anie.201510551.


Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues.

Buss I, Kalayda G, Lindauer A, Reithofer M, Galanski M, Keppler B J Biol Inorg Chem. 2012; 17(5):699-708.

PMID: 22456982 DOI: 10.1007/s00775-012-0889-9.


References
1.
Bugarcic Z, Heinemann F, van Eldik R . Substitution reactions of [Pt(terpy)X]2+ with some biologically relevant ligands. Synthesis and crystal structure of [Pt(terpy)(cyst-S)](ClO4)2.0.5H2O and [Pt(terpy)(guo-N7)](ClO4)2.0.5guo.1.5H2O. Dalton Trans. 2004; (2):279-86. DOI: 10.1039/b311056g. View

2.
Wong E, Giandomenico C . Current status of platinum-based antitumor drugs. Chem Rev. 2001; 99(9):2451-66. DOI: 10.1021/cr980420v. View

3.
Jakupec M, Galanski M, Keppler B . Tumour-inhibiting platinum complexes--state of the art and future perspectives. Rev Physiol Biochem Pharmacol. 2003; 146:1-54. DOI: 10.1007/s10254-002-0001-x. View

4.
Summa N, Schiessl W, Puchta R, van Eikema Hommes N, van Eldik R . Thermodynamic and kinetic studies on reactions of Pt(II) complexes with biologically relevant nucleophiles. Inorg Chem. 2006; 45(7):2948-59. DOI: 10.1021/ic051955r. View

5.
Evans B, Raju K, Calvert A, Harland S, Wiltshaw E . Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep. 1983; 67(11):997-1000. View